- Company
- Sales of Losartan are plummeting due to the impurity crisis
- by Chon, Seung-Hyun May 9, 2022 06:03am
- The prescription market for the hypertension drug "Losartan" has shrunk significantly. It is analyzed that a large number of prescription gaps occurred due to detection of excess impurities at the end of last year. According to UBIST, a pharmaceutical research agency, on the 2nd, the outpatient prescription amount of Losartan-containing drugs in
- Hunterase makes new record in overseas exports
- by Chon, Seung-Hyun May 6, 2022 05:46am
- The homegrown rare disease treatment ‘Hunterase’ made record-high performance in its exports. By expanding the number of countries in the global market, the company generated over four times its domestic sales overseas. According to GC Cross on the 5th, Hunterase recorded sales of &8361;22.6 billion in Q1 this year. This is a 72.5%, &8361
- Company
- Breast cancer supplement Nerlynx is available in hospitals
- by Eo, Yun-Ho May 6, 2022 05:46am
- Breast cancer supplement Nerlynx has become available in hospitals. According to related industries, Tyrosine kinase inhibitor Nerlynx (Neratinib), which inhibits Bixink's HER2 protein, passed the Drug Committee (DC) of medical institutions such as Seoul National University Hospital. However, as it is still non-reimubrsement, it is expecte
- Opinion
- [Reporter’s View] Now is the time for drug reclassification
- by Lee, Tak-Sun May 6, 2022 05:46am
- 10 years have already passed since the heated discussion arose on the drug reclassification and sale of over-the-counter drugs in non-pharmacy venues. As the Korean saying goes, even nature can change in one decade. In that not-so-long but also an epoch of a period in terms of change, many drugs have established safety profiles and await bet
- Policy
- Only 40% of asthma pts undergo Pulmonary function testing
- by Lee, Tak-Sun May 6, 2022 05:46am
- Although it is recommended to take pulmonary function test at least once a year to manage diseases in asthma patients, only less than half of all patients are tested. The HIRA announced on the 3rd that it will analyze and disclose the results of the 2020 (8th) asthma adequacy evaluation to mark World Asthma Day. As a result of the evaluation,
- Company
- Hospitals Busy Introducing Kymriah
- by Moon, sung-ho May 6, 2022 05:45am
- The full-fledged administration of Kymriah, a Korean Novartis CAR-T treatment called an "ultra-high-priced anticancer drug," has begun. Hospitals have also become busy as the administration of treatments at four large hospitals in Korea has begun in earnest. At the beginning of last year's domestic approval, it was a wait-and-see attitude, bu
- Company
- Risk of Impurities in Treatment of Schizophrenia
- by Chon, Seung-Hyun May 4, 2022 06:04am
- The health authorities have started to check for impurities on Quetiapine-based drugs used as schizophrenia treatments. It is a new type of nitrosamines impurity that has not appeared before. The number of drugs that have raised the risk of impurities in Korea has increased to 10. According to the industry on the 3rd, the MFDS recently ord
- Company
- Insurance benefit for Vemlidy expanded in Korea
- by May 4, 2022 06:03am
- The health authorities have extended the insurance benefit of Gilead Science’s chronic hepatitis B treatment ‘Vemlidy (tenofovir ala fenamide)’ to liver cirrhosis and hepatocellular carcinoma, accelerating the generation shift of HBV drugs in Korea. According to the Ministry of Health and Welfare on the 3rd, Vemlidy’s reimbursement sta
- Opinion
- [Reporter’s View] Use of maintenance and adjuvant therapies
- by Eo, Yun-Ho May 4, 2022 06:03am
- Continuous administration of a drug for ‘prevention.' This is not a new concept. Patients have been taking drugs to ‘manage’ their chronic condition for a long time, and drugs such as anticoagulants exist for the purpose of prevention. This only became an issue after the concept of maintenance and adjuvant therapies were introduced
- Company
- Boryung challenges patent for leukemia drug Tasigna
- by Kim, Jin-Gu May 4, 2022 06:03am
- Boryung has challenged Novartis' patent for its leukemia treatment Tasigna (Nilotinib). If the patent avoidance challenge is successful, Boryung is expected to be able to aim for synergy with the previously released Glivec (Imatinib mesilate) generic. According to the pharmaceutical industry on the 3rd, Boryung recently requested a passive
